{"id":659372,"date":"2023-07-13T02:16:01","date_gmt":"2023-07-13T02:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=659372"},"modified":"2023-07-13T02:16:01","modified_gmt":"2023-07-13T02:16:01","slug":"primary-sclerosing-cholangitis-psc-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-202332-delveinsight-genfit-gilead-immunic-ipsen-sirnaomics-scohia-mirum-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-sclerosing-cholangitis-psc-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-202332-delveinsight-genfit-gilead-immunic-ipsen-sirnaomics-scohia-mirum-pharma_659372.html","title":{"rendered":"Primary Sclerosing Cholangitis (PSC) Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-32) – DelveInsight | Genfit, Gilead, Immunic, Ipsen, Sirnaomics, SCOHIA, Mirum Pharma"},"content":{"rendered":"
\n
\"Primary<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Primary Sclerosing Cholangitis Market size in the 7MM is expected to increase at a CAGR of about 17.2% during the forecast period. As per DelveInsight, the Primary Sclerosing Cholangitis Market is anticipated to evolve immensely in the coming years owing to the expected launch of therapies and the rise in the number of cases of Primary Sclerosing Cholangitis (PSC) in the 7MM.<\/div>\n

DelveInsight’s “Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Sclerosing Cholangitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Primary Sclerosing Cholangitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Primary Sclerosing Cholangitis treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Primary Sclerosing Cholangitis: An Overview<\/strong><\/p>\n

According to the American Liver Foundation, primary sclerosing cholangitis (Primary Sclerosing Cholangitis) is a chronic or long-term disease that slowly damages the bile ducts. In Primary Sclerosing Cholangitis patients, the bile ducts are blocked due to inflammation and scarring or fibrosis, leading to the accumulation of bile in the liver, which gradually damages liver cells and causes cirrhosis or fibrosis of the liver. As cirrhosis progresses and the amount of scar tissue in the liver increases, the liver slowly loses its ability to function. The scar tissue may block the drainage of the bile ducts leading to bile infection.<\/p>\n

Despite clinical trials of numerous pharmacotherapies over several decades, safe and effective medical therapy remains to be established. High-dose ursodeoxycholic acid is used to treat Primary Sclerosing Cholangitis patients as there is a trend toward increased survival. Dominant bile duct stenoses should be treated endoscopically; however, liver transplantation is the only therapeutic option for patients with advanced disease.<\/p>\n

Many molecules are in the pipeline to treat Primary Sclerosing Cholangitis patients across the 7MM to cater to their needs. Some major products are anticipated to hit the market during the forecast period (2023–2032), including norUrsodeoxycholic acid, and HTD1801.<\/p>\n

Primary Sclerosing Cholangitis Market Key Facts<\/strong><\/p>\n